Previous studies demonstrated that inhibition of intestinal NPC1L1 prevents gallstone formation; in addition, ezetimibe, a selective NPC1L1 inhibitor, prevents gallstone formation in mice, indicating that NPC1L1 is a valid therapeutic target against CGD [26]. The gene discussed is NPC1L1; the disease is gallstones.